NCT05936138View on ClinicalTrials.gov

A Study of LY3502970 in Participants With Normal and Impaired Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 13, 2023

Primary Completion Date

April 11, 2024

Study Completion Date

April 11, 2024

Conditions
Renal InsufficiencyHealthy
Interventions
DRUG

LY3502970

Administered orally.

Trial Locations (4)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, Miami

33147

Advanced Pharma CR, LLC, Miami

37920

Alliance For multispecialty Research, LLC, Knoxville

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY